Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response

• Published in: Clinical cancer research Vol. 14; no. 15; pp. 4877 - 4882
• Main Authors: Wu, Jenn-Yu, Wu, Shang-Gin, Yang, Chih-Hsin, Gow, Chien-Hung, Chang, Yih-Leong, Yu, Chong-Jen, Shih, Jin-Yuan, Yang, Pan-Chyr
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 01.08.2008
• Subjects: Aged; Aged, 80 and over; Antineoplastic agents; Antineoplastic Agents - pharmacology; Biological and medical sciences; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Drug Resistance, Neoplasm; EGFR; Exon 20; Exons; Female; Gefitinib; Humans; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Male; Medical sciences; Middle Aged; Mutation; Mutations; Pharmacology. Drug treatments; Pneumology; Quinazolines - pharmacology; Receptor, Epidermal Growth Factor - genetics; Treatment Outcome; Tumors of the respiratory system and mediastinum; Antineoplastic agent; Lung disease; Enzyme; Tyrosine kinase inhibitor; Respiratory disease; Quinazoline derivatives; Transferases; Lung cancer; Treatment efficiency; Enzyme inhibitor; Malignant tumor; Bronchopulmonary; Epidermal growth factor receptor; Growth factor receptor; Exon; Bronchus disease; Genetics; Mutation; Gefitinib; Protein-tyrosine kinase; Cancer

Purpose: Clinical reports about responsiveness to gefitinib treatment in patients of non-small cell lung cancer (NSCLC) with mutations in exon 20 of epidermal growth factor receptor (EGFR) are limited. To increase understanding of the influence of exon 20 mutations on NSCLC treatment with gefitinib,...